I'm really pleased to be joined by the Regeneron team. Next to me is Chris ... is the best way to deliver long-term shareholder value is continuing to invest in our own internal R&D capabilities.

Ohtuvayre's rapid US launch boosts Verona's growth with Q1 2025 sales up 95%. Read more on VRNA stock's blockbuster potential ...

SAN FRANCISCO, June 13, 2025 (GLOBE NEWSWIRE) -- 23andMe Holding Co. (“23andMe” or the “Company”) (OTC: MEHCQ), a leading human genetics and biotechnology company, today announced that it has entered ...

Me was founded in 2006 and pioneered the direct-to-consumer genetic testing model. Customers responded positively, ordering ...

Twenty-seven states and Washington, D.C. are suing to stop 23andMe (ME) from selling customers’ personal information without ...

Public exchange offer for all shares of CureVac where each share of CureVac will be exchanged for approx. $5.46 in BioNTech American Depositary Shares (“ADSs”), representing a premium of 55% to ...

REGENERON PHARMACEUTICALS INC (REGN) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the ...

REGENERON PHARMACEUTICALS INC (REGN) is a large-cap value stock in the Biotechnology & Drugs industry. The rating using this strategy is 86% based on the firm’s underlying fundamentals and the ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 13 Biotech Stocks with Huge Upside Potential. JPMorgan has maintained its Overweight rating on Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) ...

Regeneron signed a deal with China-based Hansoh Pharma for HS-20094, an investigational, late-stage anti-obesity asset. Per ...

REGN)’ solid cash position alone warrants a valuation far higher than current levels. JPMorgan anticipates several catalysts over the next six months that will help reset its value. Recently ...